Of patients originally receiving 1L PBC, 24.1% (252 of 1044) initiated 2L IO monotherapy, 13.3% (139 of 1044) initiated other therapies, and 8.3% (87 of 1044) stayed on PBC in 2L (Figure 2). Here, DLAT is linked to primary biliary cholangitis.